Scott Steven Ganser

US Patent:

6586474, Jul 1, 2003

Filed:

Mar 23, 2001

Appl. No.:

09/816575

Inventors:

Ronald Keith Webber - St. Charles MO
Richard C. Durley - Chesterfield MO
Alok K. Awasthi - Skokie IL
Arija A. Bergmanis - Des Plaines IL
Kam F. Fok - St. Louis MO
Scott S. Ganser - Chicago IL
Timothy J. Hagen - Gurne IL
E. Ann Hallinan - Evanston IL
Brian S. Hickory - Wildwood MO
Pamela T. Manning - Labadie MO
Michael Mao - Chesterfield MO
Alan E. Moormann - Weldon Spring MO
Barnett S. Pitzele - Skokie IL
Michelle A. Promo - Chesterfield MO
Richard R. Schartman - Evanston IL
Jeffrey A. Scholten - Chesterfield MO
Jeffrey S. Snyder - Manchester MO
Mihaly V. Toth - St. Louis MO
Mahima Trivedi - Glenview IL
Sofya Tsymbalov - Skokie IL
Foe Siong Tjoeng - Ballwin MO

Assignee:

Pharmacia Corporation - St. Louis MO

International Classification:

A61K 31195

US Classification:

514562, 560153, 562557

Abstract:

The present invention relates to amidino compounds and salts and prodrugs thereof. In another embodiment the present invention also provides a use of the present compounds in therapy, particular as nitric oxide synthase inhibitors. In a further embodiment, the present invention provides methods of making the amidino compounds.

US Patent:

6914158, Jul 5, 2005

Filed:

Apr 1, 2004

Appl. No.:

10/815375

Inventors:

Ronald Keith Webber - Charles MO, US
Richard C. Durley - Chesterfield MO, US
Alok K. Awasthi - Skokie IL, US
Arija A. Bergmanis - Des Plaines IL, US
Kam F. Fok - St. Louis MO, US
Scott S. Ganser - Chicago IL, US
Timothy J. Hagen - Gurne IL, US
E. Ann Hallinan - Evanston IL, US
Brian S. Hickory - Wildwood MO, US
Pamela T. Manning - Labadie MO, US
Michael Mao - Chesterfield MO, US
Alan E. Moormann - Weldon Springs MO, US
Barnett S. Pitzele - Skokie IL, US
Michelle A. Promo - Chesterfield MO, US
Richard R. Schartman - Evanston IL, US
Jeffrey A. Scholten - Chesterfield MO, US
Jeffrey S. Snyder - Manchester MO, US
Mihaly V. Toth - St. Louis MO, US
Mahima Trivedi - Glenview IL, US
Sofya Tsymbalov - Skokie IL, US
Foe Siong Tjoeng - Ballwin MO, US

Assignee:

Pharmacia Corporation - St. Louis MO

International Classification:

C07C323/00

US Classification:

562557

Abstract:

The present invention relates to amidino compounds and salts and prodrugs thereof. In another embodiment the present invention also provides a use of the present compounds in therapy, particular as nitric oxide synthase inhibitors. In a further embodiment, the present invention provides methods of making the amidino compounds.

US Patent:

7102013, Sep 5, 2006

Filed:

Dec 17, 2002

Appl. No.:

10/321969

Inventors:

Ronald Keith Webber - St. Charles MO, US
Richard C. Durley - Chesterfield MO, US
Alok K. Awasthi - Skokie IL, US
Arija A. Bergmanis - Des Plaines IL, US
Kam F. Fok - St. Louis MO, US
Scott S. Ganser - Chicago IL, US
Timothy J. Hagen - Gurne IL, US
E. Ann Hallinan - Evanston IL, US
Brian S. Hickory - Wildwood MO, US
Pamela T. Manning - Labadie MO, US
Michael Mao - Chesterfield MO, US
Alan E. Moormann - Weldon Springs MO, US
Barnett S. Pitzele - Skokie IL, US
Michelle A. Promo - Chesterfield MO, US
Richard R. Schartman - Evanston IL, US
Jeffrey A. Scholten - Chesterfield MO, US
Jeffrey S. Snyder - Manchester MO, US
Mihaly V. Toth - St. Louis MO, US
Mahima Trivedi - Glenview IL, US
Sofya Tsymbalov - Skokie IL, US
Foe Siong Tjoeng - Ballwin MO, US

Assignee:

Pharmacia Corporation - St. Louis MO

International Classification:

C07D 233/40
C07C 271/00
C07C 323/00

US Classification:

5483195, 5483171, 560148, 562557

Abstract:

Method of making an alpha-amino acid compound having the structure of Formula 32: comprising treating under hydrolyzing conditions a hydantoin compound having the structure of Formula 33: where the substituents are described herein.

US Patent:

7196118, Mar 27, 2007

Filed:

Jan 10, 2005

Appl. No.:

11/032650

Inventors:

Ronald Keith Webber - St. Charles MO, US
Richard C. Durley - Chesterfield MO, US
Alok K. Awasthi - Skokie IL, US
Arija A. Bergmanis - Des Plaines IL, US
Kam F. Fok - St. Louis MO, US
Scott S. Ganser - Chicago IL, US
Timothy J. Hagen - Gurne IL, US
E. Ann Hallinan - Evanston IL, US
Brian S. Hickory - Wildwood MO, US
Pamela T. Manning - Labadie MO, US
Michael Mao - Chesterfield MO, US
Alan E. Moormann - Weldon Springs MO, US
Barnett S. Pitzele - Skokie IL, US
Michelle A. Promo - Chesterfield MO, US
Richard R. Schartman - Evanston IL, US
Jeffrey A. Scholten - Chesterfield MO, US
Jeffrey S. Snyder - Manchester MO, US
Mihaly V. Toth - St. Louis MO, US
Mahima Trivedi - Glenview IL, US
Sofya Tsymbalov - Skokie IL, US
Foe Siong Tjoeng - Ballwin MO, US

Assignee:

Pharmacia Corporation - St. Louis MO

International Classification:

A61K 31/195

US Classification:

514562

Abstract:

The present invention relates to amidino compounds and salts and prodrugs thereof. In another embodiment the present invention also provides a use of the present compounds in therapy, particular as nitric oxide synthase inhibitors. In a further embodiment, the present invention provides methods of making the amidino compounds.

US Patent:

20020019563, Feb 14, 2002

Filed:

Mar 23, 2001

Appl. No.:

09/816577

Inventors:

Ronald Webber - St. Charles MO, US
Richard Durley - Chesterfield MO, US
Alok Awasthi - Skokie IL, US
Arija Bergmanis - Des Plaines IL, US
Scott Ganser - Chicago IL, US
Timothy Hagen - Gurne IL, US
E. Hallinan - Evanston IL, US
Donald Hansen - Skokie IL, US
Brian Hickory - Wildwood MO, US
Alan Moormann - Weldon Springs MO, US
Barnett Pitzele - Skokie IL, US
Michelle Promo - Chesterfield MO, US
Richard Schartman - Evanston IL, US
Jeffrey Snyder - Manchester MO, US
Mahima Trivedi - Glenview IL, US
Sofya Tsymbalov - Skokie IL, US

International Classification:

C07C323/25

US Classification:

562/477000, 562/556000

Abstract:

The present invention relates to S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine, or a pharmaceutically acceptable salt thereof.

US Patent:

20020038021, Mar 28, 2002

Filed:

Dec 7, 2000

Appl. No.:

09/732208

Inventors:

Kathleen Barton - Lake Forest IL, US
Thomas Borchardt - Pleasant Prairie WI, US
Marlon Carlos - Des Plaines IL, US
Subhash Desai - Wilmette IL, US
Leonard Ferro - Highland Park IL, US
Henry Gaud - Evanston IL, US
Scott Ganser - Park City IL, US
Clay Little - Lindenhurst IL, US
Partha Mudipalli - Skokie IL, US
Mark Pietz - Grayslake IL, US
Daniel Pilipauskas - Glenview IL, US
Yuen-Lung Sing - St. Louis MO, US
Glenn Stahl - Buffalo Grove IL, US
Joseph Wieczorek - Cary IL, US
Chris Yan - Plainsboro NJ, US

International Classification:

C07J017/00
C07J001/00
C07J021/00

US Classification:

540/002000, 540/116000, 540/041000

Abstract:

A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.

US Patent:

20020045746, Apr 18, 2002

Filed:

Dec 7, 2000

Appl. No.:

09/732209

Inventors:

Kathleen Barton - Lake Forest IL, US
Thomas Borchardt - Pleasant Prairie WI, US
Marlon Carlos - Des Plaines IL, US
Subhash Desai - Wilmette IL, US
Leonard Ferro - Highland Park IL, US
Henry Gaud - Evanston IL, US
Scott Ganser - Park City IL, US
Clay Little - Lindenhurst IL, US
Partha Mudipalli - Skokie IL, US
Mark Pietz - Grayslake IL, US
Daniel Pilipauskas - Glenview IL, US
Yuen-Lung Sing - St. Louis MO, US
Glenn Stahl - Buffalo Grove IL, US
Joseph Wieczorek - Cary IL, US
Chris Yan - Plainsboro IL, US

International Classification:

C07J001/00
C07J021/00

US Classification:

540/002000, 540/041000

Abstract:

A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.

US Patent:

20030083493, May 1, 2003

Filed:

Jul 9, 2002

Appl. No.:

10/191626

Inventors:

Kathleen Barton - Lake Forest IL, US
Thomas Borchardt - Pleasant Prairie WI, US
Marlon Carlos - Des Plaines IL, US
Subhash Desai - Wilmette IL, US
Leonard Ferro - Highland Park IL, US
Henry Gaud - Evanston IL, US
Scott Ganser - Park City IL, US
Clay Little - Lindenhurst IL, US
Partha Mudipalli - Skokie IL, US
Mark Pietz - Grayslake IL, US
Daniel Pilipauskas - Glenview IL, US
Yuen-Lung Sing - St. Louis MO, US
Glenn Stahl - Buffalo Grove IL, US
Joseph Wieczorek - Cary IL, US
Chris Yan - Vernon Hills IL, US

International Classification:

C07J053/00

US Classification:

540/047000

Abstract:

A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.